Related Experiment Video
Updated: Jul 21, 2025
07:49
Application of Consistent Massage-Like Perturbations on Mouse Calves and Monitoring the Resulting Intramuscular Pressure Changes
Published on: September 20, 2019
5.7K
A Prochlorperazine-Induced Decrease in Autonomous Muscle Activity during Hindlimb Unloading Is Accompanied by
Kristina A Sharlo1, Irina D Lvova1, Sergey A Tyganov1
1Myology Laboratory, Institute of Biomedical Problems, Russian Academy of Sciences, 123007 Moscow, Russia.
Current Issues in Molecular Biology
|July 28, 2023
Summary
Prochlorperazine prevents muscle fiber changes and function decline caused by disuse. This drug may block the transformation of slow muscle fibers to fast, fatigable fibers in rats.
Area of Science:
- Muscle physiology and cellular biology
- Pharmacology of skeletal muscle adaptation
- Biomedical research on disuse atrophy
Background:
- Skeletal muscle disuse causes pathological activity and a shift from slow to fast fiber types.
- Fast-type fibers fatigue more easily, leading to reduced muscle function.
- Previous studies indicated prochlorperazine can reduce electrical activity in unloaded rat soleus muscles.
Purpose of the Study:
- To investigate the effect of prochlorperazine on fiber-type transformation in disused skeletal muscle.
- To determine if prochlorperazine can prevent the functional decline associated with muscle disuse.
- To explore the potential mechanisms, including calcium and reactive oxygen species (ROS) signaling, involved in prochlorperazine's effects.
Main Methods:
- Administration of prochlorperazine injections to rats.
- Induction of skeletal muscle disuse in a rat model.
- Analysis of skeletal muscle fiber-type composition.
- Investigation of calcium and ROS-related signaling pathways.
Main Results:
- Prochlorperazine administration blocked the slow-to-fast fiber-type transformation in disused rat skeletal muscles.
- The drug's action may be linked to modulation of calcium and ROS signaling.
- These findings suggest a potential therapeutic role for prochlorperazine in mitigating disuse-induced muscle dysfunction.
Conclusions:
- Prochlorperazine effectively prevents detrimental fiber-type changes in disused skeletal muscle.
- The mechanism may involve the regulation of intracellular calcium and reactive oxygen species.
- This research highlights prochlorperazine as a potential therapeutic agent for conditions involving skeletal muscle disuse.
Related Concept Videos
01:28Classification of Skeletal Muscle Relaxants
2.5K
Skeletal muscle relaxants are a group of drugs that can reduce muscle stiffness and induce temporary paralysis to relieve pain. These agents can act centrally to reduce muscle tone or spasms in painful conditions such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), or spinal injuries; they are called antispasmodics or spasmolytics.
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
2.5K
01:21Skeletal Muscle Relaxants: Adverse Effects
401
Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
Unlike...
401
01:27Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions
458
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
Although all competitive neuromuscular blockers are designed...
458
01:09Peripherally and Centrally Acting Muscle Relaxants: A Comparison
3.4K
Skeletal muscle relaxants can target the central nervous system [CNS] to reduce muscle tension or act directly at the neuromuscular junction to induce temporary paralysis. These two classes of muscle relaxants are called centrally acting muscle relaxants and peripherally acting muscle relaxants. They differ in their action, mechanism, administration route, and clinical uses.
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic...
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic...
3.4K
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
311
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
311
01:17Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action
1.9K
Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
1.9K